National and Kapodistrian University of Athens
Επίπεδα νευροτενσίνης (NT), εκλυτικής ορμόνης της κορτικοτροπίνης (CRH) και ιντερλευκίνης-33 (IL-33) στον ορό ασθενών με δερματική μαστοκυττάρωση (ΔΜ) και η επίδρασή τους στην ενεργοποίηση των ανθρωπίνων καλλιεργούμενων μαστοκυττάρων
Abstract
dc:descriptionObjective: The goals of the present study are: a) the influence of neurotensin (NT), corticotropin releasing hormone (CRH) and interleukin-33 (IL-33) in the way with which the human cultured mast cells release substances, when they are cultured in media enhanced or not with interleukin-4 (IL-4). Moreover, b) the influence of the previous mentioned substances and of their combinations in the gene expression, intracellular synthesis and extracellular release of interleukin-31 (IL-31) from the stimulated mast cells when they are cultured in media enhanced or not with IL-4 and are sensitized or not with IgE/anti-IgE. Final goal of the present study was c) the measurement of the levels of NT, CRH and IL-33 at the serum of patients suffering from cutaneous mastocytosis (CM).Cells, subjects and methods: At the present study we used human leukemic mast cells (LAD2). They were donated from Dr. Kirshenbaum from the National Institute of health (NIH, Bethesda, MD, USA) and were obtained from a patient suffering from mast cell leukemia. LAD2 were cultured in specific flasks, in which LAD2 were placed at concentration 105/ml of culture media (StemPro-34 serum-free medium, Invitrogen, Carlsbad, CA, USA). Recombinant human stem cell factor (rhSCF, Biovitrum, Sweden) 100 ng/ml, penicillin 1%, streptomycin 1% and glutamin 1% were added in the media. When LAD2 were stimulated with rhIL-4 (recombinant human IL-4, R&D systems, Mineapolis, MN) and were sensitized with IgE, IL-4 100 ng/ml and IgE 1 μg/ml (human IgE, EMD Millipore, San Diego, CA) were added in the media for 2 weeks and 12 hours respectively, before cultured cells were washed off with their relative media and finally stimulated with the corresponding substances for 24 hours. The substances which were used for the 24-hour stimulation of LAD2 were CRH at 10 μΜ (Sigma-Aldrich, St Louis, MO), ΝΤ 1 μM (Sigma-Aldrich, St Louis, MO), IL-33 at 10 ng/ml, (R&D Sytsems, Minneapolis, MN), anti-IgE at 1 μg/ml, (Life Technologies, Carlsbad, CA) and SP at 2 μΜ, (Sigma-Aldrich, St Louis, MO), as well as their combination. The final concentrations of the substances under investigation were done in the corresponding media relatively to the condition which was studied each time. LAD2 were cultured in specific tissue culture room where CO2 was 5% and temperature 37 0C, and were used in their logarithmic phase of development. Mast cells stimulated or not with the previous mentioned substances and sensitized or not with IgE/anti-IgE in enhanced or not IL-4 media were investigated relatively to their ability to express genetically, synthesize intracellularly and release the newly described interleukin-31 (IL-31), after we proved if the investigated substances degranulate preformed substances from mast cells or if they release newly synthesized ones from them.The levels of NT, CRH and IL-33 were measured in patients’ serum suffering from CM. These patients were 20 Caucasian children and their age was 5 + 4 years with maculopapular CM (n=5), diffuse (n=4) or cutaneous mastocytoma (n=11). These children presented at the pediatric outpatient clinic of A’ Dermatologic Clinic of the University of Athens at “Andreas Syggros” Hospital, as well as the B’ Allergiologic Department of Children’s Hospital “Panagiotis and Aglaia Kyriakou” of the University of Athens. Controls were 10 Caucasian children, 4,5 + 3 years (n=10), who presented for a routine check-up at the pediatric outpatient clinic of A’ Dermatologic Clinic of “Andreas Syggros” Hospital of the University of Athens. Both patients’ and controls’ parents were informed relatively to the purpose of our study and then they signed a consent form according to the principles of Helsinki. Also, all patients’ parents completed their children’s personal history in detail. Methods which were followed were: a) β-hexosaminidase release (β-hex), so as to clarify the way mast cells release substances when they are under the influence of the investigated substances, using as positive control SP, b) lysis of LAD2 mast cells under all the different investigated conditions, using a light sensitive solution, which consisted by Buffer 10x (Cell Signaling Technology), PBS and PMSF (Cell Signaling Technology). This technique allowed the collection, under light sensitive conditions of the intracellular content of the mast cells, in order to measure the intracellular synthesis of IL-31 and its intracellular storage, c) the technique of reverse transcription followed by the quantitative polymerase chain reaction (qPCR), so as we investigate the gene expression of IL-31 from the cultured mast cells, under the pre-mentioned various conditions and d) the Enzyme-Linked Immunosorbent Assay (ELISA), in order we measure the levels of both the intracellular synthesis and the release of IL-31 (human IL-31, R&D Systems, Minneapolis, MN) from mast cells under all the investigated conditions. Moreover, ELISA was also used for measuring the levels of NT (human Neurotensin, NT ELISA kit, CSB-E09144h, Cusabio), CRH (human corticotropin releasing hormone, CRH ELISA Kit, CSB-E06872h, Cusabio) and IL-33 (human IL-33 ELISA Kit, EA 100585, Origene) in the serum of both patients suffering from CM and controls with similar characteristics.Results: Mast cells express the gene, synthesize intracellularly and release the newly described IL-31 when IL-33 stimulates mast cells on its own, but not in response to NT, CRH and SP. However, when NT, CRH or SP co-stimulate mast cells with IL-33, and especially when IL-33 co-stimulates mast cells with SP, all above activities of mast cells relatively to IL-31 appear increased. The increase becomes more intense when IL-4 is added in the media or mast cells are sensitized with IgE/anti-IgE, but the most intense responses appear when both IL-4 and IgE/anti-IgE co-exist, and especially at the condition at which IL-33 co-stimulates with SP the mast cells. We suggest that mast cells don’t degranulate IL-31, as we proved through our experiments that NT, CRH and IL-33 don’t degranulate one of the known pre-formed substances of mast cells, β-exosaminidase; while SP degranulates it. Levels of NT, CRH and IL-33 were not increased at patients’ with CM serum comparatively with the controls’ one. Conclusion: The exacerbation of both the symptoms of inflammatory, allergic and autoimmune diseases, with pruritus being the main one, and their prognosis, and especially under emotional and physical stress, may be explained through the increase of the levels of IL-31 when mast cells are influenced by substances from their microenvironment, in which IL-33, CRH, NT and SP are increased, according to the bibliography. Mast cells are among the most important cells of the above mentioned diseases, as they induce and enhance both the innate and the adaptive immune system, through their numerous and various receptors or mediators, which among others, make mast cells able to recruit other types of cells. Recruitment of other cecll types from mast cells leads extra mediators to be released and further interactions with mast cells happen, immunologically or non-immunollogically mediated. To the best of our knowledge, our study is the first which proves that the newly described IL-31, important cytokine to inflammatory, allergic and autoimmune diseases, is expressed at the gene level, synthesized intracellularly and released from mast cells, when IL-33, CRH and NT stimulate mast cells. The above mentioned activities of mast cells relatively to the IL-31 are enhanced when mast cells response with IgE-mediated mechanisms or IL-4 exists in their microenvironment or even increased activities appear when all the above conditions co-exist and the person is emotionally or physically stressed. IL-4 is released from recruited white cells; but is also shown that released by mast cells stimulates further the production of leukotrienes from mast cells, with positive feedback to themand thus their advanced reactive hyperplasia. IL-4 promotes the increased production of IgE, enhancing again the effects of mast cells. Levels of NT, CRH and IL-33 in the serum of patients with CM serum are not increased comparing to the controls serum. Given that levels of IL-31 are not increased in serum of patients with CM, according to a publication, the lack of any increase in serum NT, CRH or IL-33 suggests that some relationship may be importnant locally in the skin. However, the levels of the same substances may be increased at the serum of SM patients, as levels of IL-31 are increased at them, according to the bibliography.Our results show that mast cells are multipotent and can be maximally stimulated by a combination of triggers. It is, therefore, necessary to develop effective inhibitors of the synthesis and release of their proinflammatory mediators. Recent example consists the higly promising treatment of the inhibitors of IL-4 (dupilumab) at diseases, such as atopic dermatitis, which are characterized both from majority of mast cells and IL-31 consists index of their severity and of the intense of the pruritus which appears to these.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Petra, Anastasia
- Πετρά, Αναστασία
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43585